Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon May 26, 2024 9:36am
165 Views
Post# 36057837

RE:Winning the Battle against Septic Shock

RE:Winning the Battle against Septic Shock

Paradigm's last target price ( April) was based on a 120,000 targeted patient population and 35% market penetration 

Spectral's latest EBITDA analysis is based on 140,000 but provides no SP target like Paradigm . 

140k/120k  = 1.16. 

If paradigm used the same number of patients in their assumptions, their target would presumably be 16% higher or over $2.

Paradigm also says that they consider their analysis and target to be based on very conservative assumptions. 

Spectral also seems to be using a very conservative " per column" projected prices. Of course results that greatly exceeded expected results in terms of mortality benefit and other outcomes ( think reduced hospital costs from reduced ventilator use, etc) should command a higher price - one would think. 

MM 

 

<< Previous
Bullboard Posts
Next >>